Citius Pharmaceuticals Inc (CTXR)

[conix]

CTXR Highlights


*Low Risk/HIGH Reward Strategy using the 505(b)2 regulatory pathway products

*Lower cost; Much faster route to Approval than the Traditional Historical/Normal route

*Unique Indications/Minimal Competition

*One Phase 3 Product; One Phase 2 Product; One Pre-Clinical; Targeted Acquisitions

*Phase 3 - "Mino-Lok" - Antibiotic lock therapy that salvages central lines/catheters that cause bloodstream infections; Over $1B market

*"Mino-Wrap"(101) - Gelatin Film Bioabsorbable Extended Release Wrap for Prevention of Breast Tissue Infections

*"Halo-Lido"(002) - Lidocaine Prescription Strength Topical for Hemorrhoid Treatment - Phase 2

*Hoping to be first FDA-approved Prescription product to treat Hemorrhoids

*Heavy Insider Ownership and Investment

Background:

Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.


Market Capitalization: $26 million
Current Price: $1.XX
YTD H-L: $3.14 - 0.85
Symbol: CTXR

Website: www.citiuspharma.com